Bullish Case: INSP’s 27.8% 90-day rebound to $57.19 shows mean reversion can overpower the long-term decline. Calls traded 43% more than puts, while Helium’s price-density peaks cluster around $55–60 and $50–55. If reimbursement, onboarding, or guidance improves, compressed Helium IV for September–March (38–60%) versus market IV (48–69%) could enable a volatility-supported move toward $65–75.

Bearish Case: The rebound has stalled near $57, with INSP still 36.5% below a year ago and priced at 29.6x book. Helium’s historical-return surface contains a pronounced negative tail extending roughly to -84%, while its AI forecast is -2.76%. Payer or reimbursement disappointment could revive rich downside skew: December $55 puts imply 67.4% volatility, and November downside strikes reach 81.7%.

Potential Outcomes:

1. 42% Mean reversion: $50–62; prior $40–50 drift was too bearish as the 90-day gain shows.
2. 25% Reimbursement/onboarding improvement: $63–75; falsified by weaker guidance or stalled coverage.
3. 23% Payer/regulatory or guidance shock: $38–50; downside skew and the negative-return tail support this.
4. 10% Partnership/M&A or major catalyst: above $75; requires a disclosed event.

Oracle: mildly bearish price, but event-sensitive volatility; the August 22 expiry and September 19 expiry are the first tests. Helium IV is below market in the supplied term points, not confirmation that risk is overpriced.

August 19, 2026